

July 25, 2025

BSE Limited
Department of Corporate Services
1st Floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza
Plot No.C-1, G Block
Bandra-Kurla Complex
Bandra (East)
Mumbai – 400 051

Security Code: **523405**

Symbol: **JMFINANCIL**

Dear Sirs,

Sub: Submission of a copy of the newspaper advertisement

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy each of the advertisements published in Business Standard (English) and Sakal (Marathi) on July 25, 2025 pertaining “Special window for re-lodgement of transfer requests of physical shares”.

The contents of the above advertisements are self-explanatory. The same has also been uploaded on the Company’s website at www.jmfl.com.

Please take the above on your record and acknowledge receipt of the same.

Thank you.

Yours truly,
For **JM Financial Limited**

Hemant Pandya
Company Secretary & Compliance Officer

Encl.: as above

IL&FS Engineering Services

IL&FS Engineering and Construction Company Limited

CIN: L45201TG1988PLC008624
Regd. Office: D.No.8-2-120/113, B-Block, 1st Floor, Sarali Info Park, Road No. 2, Banjara Hills, Hyderabad - 500033
Ph: 040-40409333; Fax: 040-40409444; Email: cs@ilfsengg.com; Web: www.ilfsengg.com

NOTICE TO SHAREHOLDERS SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 02, 2025, the Company is pleased to offer one-time special window for physical shareholders to submit re-lodgment requests for the transfer of shares. The special window will be open from July 07, 2025 to January 06, 2026 and is applicable to cases where original share transfer requests were lodged prior to April 01, 2019 and were returned or rejected due to deficiencies in documentation process or any other reason. The shares re-lodged for transfer will be processed only in dematerialization form during this window.

Eligible shareholders may submit their transfer requests along with the requisite documents to the Company's Registrar and Share Transfer Agent (RTA) at KFIn Technologies Limited, Selenium Building, Tower No. B, Plot No. 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad-500032, Telangana, India. Contact No: 1800 3094 001, Email address: einward.ris@kfintech.com within stipulated period.

We urge all the eligible shareholders to take advantage of this one-time special window introduced for the benefit of investors.

Update KYC and convert physical shares into Demat mode
The Shareholders who are holding shares in physical form are requested to update their KYC and also requested to convert their physical share certificates in to dematerialized form (electronic form).

For IL&FS Engineering and Construction Company Limited
Sd/-
Rajib Kumar Routray
Company Secretary & Compliance Officer

Date: 24th July, 2025
Place: Gurugram

MAX FINANCIAL SERVICES LIMITED

CIN: L24223PB1988PLC008031
Registered Office: Bhai Mohan Singh Nagar, Village Raimajra, Tehsil Balachaur, District Nawanshahr, Punjab – 144 533
Tel: 01881-462000, 462001 Fax: 01881- 273607
Corporate Office: L20M(21), Max Towers, Plot No. – C-001/A/1, Sector – 16B, Noida – 201 301
Tel: +91-120-4696000
Website: www.maxfinancialservices.com
E-mail: investorhelpline@maxfinancialservices.in

NOTICE TO SHAREHOLDERS Special window for re-lodgement of transfer requests for physical shares

Pursuant to the Securities and Exchange Board of India ("SEBI") has issued its circular No. SEBI/HO/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025, shareholders are informed that a special window has been opened only for re-lodgement of transfer deeds along with physical share certificate(s), which were lodged prior to the deadline of April 1, 2019 and were rejected/returned/or not processed due to deficiencies in the documents/procedure issues, or other reasons.

The facility for re-lodgement will be available to the eligible physical shareholders till January 6, 2026. Shareholders are requested to re-submit their transfer requests along with physical share certificates to our Registrar & Transfer Agent, whose details are given below:

Mas Services Limited (Registrar & Transfer Agent)
T-34, 2nd Floor Okhla Industrial Area, Phase – II, New Delhi – 110 020

Contact Persons
Mr. Sharwan Mangla / Mr. O.P. Joshi
Tel No.:- 011-26387281/82/83/41320335/44796462
e-mail: investor@masserv.com

For Max Financial Services Limited
Sd/-
Piyush Soni
Company Secretary & Compliance Officer

Place: Noida
Date: July 24, 2025

JM FINANCIAL LIMITED

Corporate Identity Number: L67120MH1986PLC038784
Regd. Office : 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025.
Tel. No.: +91 22 6630 3030 • **Fax:** +91 22 6630 3223
Website: www.jmfl.com • **Email:** ecommunication@jmfl.com

NOTICE TO SHAREHOLDERS SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES (Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/ CIR/2025/97 dated July 2, 2025)

JM Financial Limited hereby informs its shareholders that the Securities and Exchange Board of India has announced special window for re-lodgement of transfer requests of physical shares, as outlined in the aforesaid circular.

To facilitate ease of investing and safeguard the rights of investors in respect of the securities purchased by them, this special window has been opened solely for the re-lodgement of physical transfer deeds that were originally lodged prior to April 1, 2019 and were rejected/returned/not processed due to deficiencies in the documents / process / or otherwise.

This facility will be available for a period of six months, beginning July 7, 2025 and ending on January 6, 2026.

Eligible shareholders are requested to re-lodge physical shares for transfer during the special window period to the Company's Registrar and Transfer Agents, **KFIn Technologies Limited, Unit: JM Financial Limited**, Selenium Building, Tower-B, Plot No. 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana – 500032, **Email:** einward.ris@kfintech.com, to avail the benefit of this facility.

For JM Financial Limited
Sd/-
Hemant Pandya
Company Secretary & Compliance Officer

Date: July 24, 2025
Place: Mumbai

Muthoot Money

GENERAL NOTICE FOR RELOCATION/ SHIFTING OF REGISTERED OFFICE OF THE COMPANY

This is to notify the General public, Customers, vendors and all stakeholders of Muthoot Money Limited ("the Company"), that the registered office of the Company presently situated at **"41 4108 A 18, OPP. Saritha Theatre, Banerji Road, Ernakulam, Kerala, India, 682018"** will be shifted or relocated to **"Muthoot Chambers, Opp. Saritha Theatre, Banerji Road, Ernakulam, Kerala, India - 682018"** upon completion of 90 days of this intimation and subject to receipt of approval of the Board of Directors of the Company.

Please disregard the General Notice dated March 21st, 2025, concerning the shifting of our registered office. This notice supersedes all previous communications and should be considered final regarding the location of our registered office.

For Muthoot Money Limited
Sd/-
Vishnu K N
Company Secretary

Place : Ernakulam
Date : 18/07/2025

BANGALORE AIRPORT HOTEL LIMITED

Name and Address of the entity seeking Proposal: BANGALORE AIRPORT HOTEL LIMITED		
Administration Block, Kempegowda International Airport, Bengaluru - 560 300 Web: www.bangaluruairport.com		
NOTICE TO EXPRESSION OF INTEREST (EOI)		
S.No.	Tender Title	Short description of Scope of Work
1	Conversion of Existing Rooms into Presidential Suite and Crew Lounge into Club Lounge with Retrofit, Modifications, and Upgradation at Taj Bangalore	1. Presidential suite: Area 2700 sqft (Room no's in 5 th floor-502, 504, 506, 508 & 510). Construction scope includes combining 5 existing rooms into one presidential suite with dismantling, Modifications to MEP and Finishings with High standard amenities. 2. Club Lounge: Area: 3370 sqft (5 th floor Existing crew lounge, room no 515, 516 & 517) Construction scope includes converting existing crew lounge into club lounge adding additional area with dismantling, Modifications to MEP and Finishings with High standard amenities like kitchen, Dinning, Entertainment, Lounge and Meeting room.

Pre Qualification Criteria & other Information: Available on BIAL website (Tenders (bangaluruairport.com)).
Submission Due Date & Time for all the above: 5th August 2025 at 20.00 Hours.
Note: Any further Addendums to this EOI shall be made available in BIAL website.
Applicants who are interested shall express their interest through E-Mail: ramesh.hegde@bialairport.com or register and login to BIAL E-Tending website (<https://www.bialtenders.com>)
Name and address of the entity seeking RFQ:
Head – Procurement & Contracts
Bangalore International Airport Limited
Alpha 3A, Kempegowda International Airport,
Devanahalli, Bengaluru - 560 300
Email for communication: ramesh.hegde@bialairport.com
Phone No: 080 – 6678 2203
www.bangaluruairport.com

भारतीय कंटेनर लिमिटेड CONTAINER CORPORATION OF INDIA LTD.	
Kolkata Cluster Area - IV East, Docked House, 8th Floor, 4th Shakespeare Street, Near Kilmardick, Kolkata - 700017	
Expression of Interest (E-EOI cum forward Auction)	
EOI Nos.	Balalore : CON/AREA-IV/WH/BS/2025-26/01 Jharsuguda : CON/AREA-IV/WH/GFCJ/2025-26/01 Durgapur : CON/AREA-IV/WH/CITJ/2025-26/01
Name of work	Online EOI for Renting out Warehouse Space on Monthly Rental Basis for a Period of 1+1+1 Year through Auction at: (1) BALASORE (2000 Sq Mtr), Bampada, Orissa (2) JHARSUGUDA (1000 Sq Mtr), Debadhi, Orissa (3) DURGAPUR (2000 Sq Mtr), Sagarbhangra, West Bengal
Estimated Cost (Approx)	Balalore : Rs.79,20,999/- incl. GST for period of 1+1+1 year Jharsuguda : Rs.24,55,167/- incl. GST for period of 1+1+1 year Durgapur : Rs.81,94,137/- incl. GST for period of 1+1+1 year
Period of Contract	1+1+1 year for all the three locations
Earnest Money Deposit (EMD) (Online)	Balalore : Rs.1,58,420/- (through e-payment) Jharsuguda : Rs.49,103/- (through e-payment) Durgapur : Rs.1,63,883/- (through e-payment)
Cost of EOI Document (Non-refundable)	
Rs.1000/- for each location (through e-payment)	
EOI Processing Fee (Non refundable)	Rs. 3540/- each for Balalore and Durgapur, inclusive of all taxes through e-payment (Non Refundable). Rs.1449/- for Jharsuguda, inclusive of all taxes through e-payment (Non Refundable).
Date of sale of EOI documents (online)	From 28.07.2025, 15:00 hrs to 18.08.2025 (upto 16:00 hrs) for all the three locations
Last Date & Time of submission of EOI (Online)	On or before 19.08.2025 upto 15:00 hrs for all the three locations
Date & Time of Opening of EOI (Online)	20.08.2025 at 15:30 hrs. for all the three locations
Eligibility Criteria	The bidder should be in the field of manufacturing or trading or clearing & forwarding agent or transporter or in logistic field for a period of last two immediate financial years prior to the last date of submission of the bid for this EOI i.e., 2023-24 & 2024-25. The bidder shall produce documentary proof of having carried out such business for the said financial years. The bidder must have a positive net worth based upon latest completed (audited) annual accounts.
Note: Bidder may submit their Bid for any location or for all three locations as per their choice. For complete details log on to www.tendersindia.com/cei . Consequent/ Addendum/ Amendments/ Clarifications etc., if any, shall be hosted on CONCOR website only (www.concorindia.co.in). Bidders are requested to visit the website regularly, contact office of CONCOR, AREA IV offices, New Delhi / Kolkata Cluster office for any doubt/ clarifications. (Ph:033-22837101-05).	
Sd/- Cluster Head, Kolkata Cluster	

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT

AVIENCE
Complete Healthcare Solution

(Please scan this QR Code to view the DRHP)

AVIENCE BIOMEDICALS LIMITED

(Formerly Known as Avience Biomedicals Private Limited)
Corporate Identification Number: U74999DL2019PLC359158

Our Company was incorporated as Avience Biomedicals Private Limited under the provisions of the Companies Act, 2013 vide certificate of incorporation dated December 23, 2019, in Delhi. Subsequently, our Company was converted into a Public Limited Company pursuant to Shareholders Resolution passed at the Extra Ordinary General Meeting of the Company held on June 26, 2024 and the name of our Company was changed from "Avience Biomedicals Private Limited" to "Avience Biomedicals Limited" vide a fresh Certificate of Incorporation dated September 03, 2024 having CIN U74999DL2019PLC359158 issued by the Registrar of Companies, Central Processing Centre, Delhi. The registered office of our company is situated at C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India. For further details, please refer to section titled "Our History and Certain Other Corporate Matters" beginning on page 232 of this Draft Red Herring Prospectus.

Registered Office: C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi-110058, India
Contact Person: Mr. Manoj Kumar; **Email ID:** info@avienbio.com; **Tel No:** 1800-12-04-636; **Website:** www.avienbio.com
Promoters of our Company: Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE (NSE EMERGE)."

THE ISSUE
INITIAL PUBLIC ISSUE OF UP TO 16,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF AVIENCE BIOMEDICALS LIMITED ("OUR COMPANY" OR "ABL" OR THE "ISSUER") AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING UP TO ₹ [•] LAKHS ("THE ISSUE") OUT OF WHICH 80,400 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AGGREGATING ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF UPTO 15,27,600 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AGGREGATING UPTO ₹ [•] LAKHS (THE "NET ISSUE"). THE ISSUE AND NET ISSUE WILL CONSTITUTE [•] AND [•] % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [•] EDITION OF [•] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [•] EDITION OF [•] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, HINDI ALSO BEING THE REGIONAL LANGUAGE OF DELHI, WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE EMERGE PLATFORM OF NSE (NSE EMERGE) FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing, extends the Bid/Issue Period for a minimum of one working day, subject to the total Bid/Issue Period not exceeding ten working days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 22B of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors (where one third of the portion available to non-institutional investors shall be reserved for applicants with application size of more than two lots and up to such lots equivalent to not more than ₹ 10 lakhs and two third of the portion available to non-institutional investors shall be reserved for applicants with application size of more than ₹ 10 lakhs) and not less than 35.00% of the Net Offer shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of IBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 307 of this Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2018 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03rd, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the offer and DRHP dated July 23, 2025 which has been filed with the Emerge Platform of NSE.

Pursuant to SEBI (ICDR) (Amendment) Regulations, 2025 on March 03rd, 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all additional eligibility criteria, the DRHP filed with the Emerge Platform of NSE (NSE EMERGE), shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the NSE at <https://www.nseindia.com/companies-listing/corporate-filings-offer-documents> and the website of the Company at www.avienbio.com and at the website of BRLM i.e. Fintellectual Corporate Advisors Private Limited at www.fintellectualadvisors.com. Our Company hereby invites the members of the public to give their comments on the DRHP filed with the Emerge Platform of NSE (NSE EMERGE) with respect to disclosures made in DRHP. The members of the public is requested to send a copy of their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned below. All comments must be received by NSE, and/or our Company and/or Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the offer on or before 5 p.m. on the 21st day from the aforesaid date of filing the DRHP with NSE EMERGE.

Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 28 of this Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on Emerge Platform of NSE (NSE EMERGE).

For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 77 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "Our History and Certain Other Corporate Matters" beginning on page 232 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
FINTELLECTUAL CORPORATE ADVISORS PRIVATE LIMITED SEBI Registration No.: INM000012944 Address: B-20, Second Floor, Sector- 1, Noida, Gautam Buddha Nagar, Uttar Pradesh- 201301 Telephone No: +91-120-4266080 Website: www.fintellectualadvisors.com Email ID: ipo@fintellectualadvisors.com Contact Person: Mr. Amit Puri/ Mr. Pramod Negi	Skyline Financial Services Private Limited SEBI Registration No.: INR000003241 Address: D-153A, 1st Floor, Okhla Industrial Area Phase-I, New Delhi - 110020, India Telephone No: 011-40450193-197 Email: ipo@skylinert.com Website: https://www.skylinert.com/ Contact Person: Mr. Anuj Rana	Mr. Manoj Kumar Address: C-11, Block-C, Community Centre, Janakpuri A-3, New Delhi- 110058, India Tel.: 1800-12-04-636; E-mail: info@avienbio.com Website: www.avienbio.com <i>Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.</i>

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For Avience Biomedicals Limited
On Behalf of the Board of Directors
Sd/-
Mr. Manoj Kumar
Company Secretary and Compliance Officer

Disclaimer: Avience Biomedicals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on July 23, 2025. The Draft Red Herring Prospectus is available on the website of NSE EMERGE at <https://www.nseindia.com/companies-listing/corporate-filings-offer-documents> and is available on the websites of the BRLM at www.fintellectualadvisors.com and also on the website of the Company www.avienbio.com. Any potential investors should note that Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 28 of this Draft Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation), except pursuant to exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transaction in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sale occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

SUPREME PETROCHEM LTD

CIN : L23200MH1989PLC054633

Regd. Office: Solitaire Corporate Park, Building No.11, 5th Floor, 167, Guru Hargovindji Marg, Andheri-Ghatkopar Link Road, Chakala, Andheri (East), Mumbai - 400093 | **Tel. No. :** 022-67091900/66935927

Fax No. : 022-40055681 | **E-mail :** investorhelpline@spl.co.in | **Website :** <http://www.supremepetrochem.com>

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in Lakhs except earnings per share data)						
Particulars		Standalone			Consolidated	
		Quarter Ended			Previous Year Ended	
		Quarter Ended	Quarter Ended	Quarter Ended	Quarter Ended	
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025	
		Unaudited	Audited	Unaudited	Audited	Unaudited
1	Total Revenue from Operations (Net)	1,38,654.29	1,53,901.95	1,57,348.83	6,02,337.52	1,40,190.80
2	Net Profit / (Loss) for the period (before tax, Exceptional and /or Extraordinary items)	10,855.33	14,289.22	16,443.21	52,542.74	11,010.71
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	10,855.33	14,289.22	16,443.21	52,542.74	11,010.71
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	8,092.24	10,688.74	12,194.50	39,052.48	8,205.05
5	Total comprehensive income for the period {comprising profit / (loss) for the period (after tax) and other Comprehensive Income (after tax)}	8,102.22	10,706.34	12,144.40	39,081.51	8,214.78
6	Equity Share Capital	3,760.83	3,760.83	3,760.83	3,760.83	3,760.83
7	Reserves (excluding Revaluation Reserves) as shown in the Audited Balance Sheet of the Previous Year				2,19,368.01	
8	Earnings Per Equity Share of Rs.2/- each					
	Basic	4.30	5.68	6.49	20.77	4.35
	Diluted	4.30	5.68	6.49	20.77	4.35

Note
1. The above is an extract of the detailed format of standalone and consolidated unaudited financial results of the Company for the first quarter ended June 30, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said unaudited financial results are available on the website of Stock Exchanges (www.bseindia.com and www.nseindia.com) and on Company's website (URL : <https://fb.gm42rbw>). The same can be accessed by scanning the QR code provided below.
2. Consequent to the execution of Share Purchase Agreement (SPA) with the promoters / shareholders of Xmolld Polymers Private Limited (Xmolld), Xmolld has become subsidiary of the Company. Since the Company has acquired control on Xmolld w.e.f. April 1, 2025, the Company's consolidated financial results includes the financial results of Xmolld only for the quarter ended June 30, 2025.

For SUPREME PETROCHEM LTD
SD/-<

